Skip to main content

Advertisement

SpringerLink
Log in

Emerging Treatments in Episodic Migraine

  • Episodic Migraine (S Nahas, Section Editor)
  • Published:
Current Pain and Headache Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

The purpose of this review is to evaluate and describe recent and emerging treatment options for episodic migraine.

Recent Findings

Recent advances have been made in better understanding the pathophysiology of migraine, which has led to further investigation of potential new pharmacologic and non-pharmacologic treatment options.

Summary

A number of new medications are emerging for the acute and preventive treatment of migraine, including CGRP monoclonal antibodies, CGRP receptor antagonists, serotonin 5-HT1F agonists, and PACAP receptor monoclonal antibodies. Additionally, newer studies on existing non-invasive neuromodulation devices including transcranial magnetic stimulation, supraorbital transcutaneous nerve stimulation, and transcutaneous vagus nerve stimulation have recently received FDA approval for use in migraine. Neuromodulation devices including percutaneous mastoid electrical stimulation, non-painful remote electrical stimulation, and caloric vestibular stimulation are undergoing further investigation and have shown promising results thus far. These new developments are expected to contribute to better treatment and decreased disability in migraine.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major Importance

  1. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol. 2017;16(11):877–97. https://doi.org/10.1016/S1474-4422(17)30299-5.

    Article  Google Scholar 

  2. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386:743–800. https://doi.org/10.1016/S0140-6736(15)60692-4.

    Article  PubMed Central  Google Scholar 

  3. Silberstein SD, Holland S, Freitag F, Dodick DW, Argoff C, Ashman E, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012;78:1337–45. https://doi.org/10.1212/WNL.0b013e3182535d20.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  4. Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55. https://doi.org/10.1111/head.13081.

    Article  PubMed  Google Scholar 

  5. Tso AR, Goadsby PJ. Anti-CGRP monoclonal antibodies: the next era of migraine prevention? Curr Treat Options Neurol. 2017;19(27):887–98. https://doi.org/10.1177/0333102416653233.

    Article  Google Scholar 

  6. Voss T, Lipton RB, Dodick DW, Dupre N, Ge JY, Bachman R, et al. A phase IIb randomized, double-blind, placebo-controlled trial of ubrogepant for the acute treatment of migraine. Cephalalgia. 2016;36:887–98. https://doi.org/10.1177/0333102416653233.

    Article  PubMed  Google Scholar 

  7. Deen M, Correnti E, Kamm K, et al. Blocking CGRP in migraine patients—a review of pros and cons. J Headache Pain. 2017;18(1):96. https://doi.org/10.1186/s10194-017-0807-1.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Hong P, Wu X, Liu Y. Calcitonin gene-related peptide monoclonal antibody for preventive treatment of episodic migraine: a meta analysis. Clin Neurol Neurosurg. 2017;154:74–8. https://doi.org/10.1016/j.clineuro.2017.01.009.

    Article  PubMed  Google Scholar 

  9. •• Dodick DW, Ashina M, Brandes JL, et al. ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia. 2018;1:333102418759786. https://doi.org/10.1177/0333102418759786. Recently published phase III trial examining CGRP receptor antibody erenumab.

    Article  Google Scholar 

  10. • Skljarevski V, Oakes TM, Zhang Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial. JAMA Neurol. 2018;75(2):187–93. https://doi.org/10.1001/jamaneurol.2017.3859. Recently published phase IIb trial examining CGRP antibody galcanezumab.

    Article  PubMed  Google Scholar 

  11. •• Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T, et al. Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med. 2017;377(22):2113–22. https://doi.org/10.1056/NEJMoa1709038. Recently published phase III trial examining CGRP antibody fremanezumab.

    Article  PubMed  CAS  Google Scholar 

  12. Somerville BW. Platelet-bound and free serotonin levels in jugular and forearm venous blood during migraine. Neurology. 1976;26:41–5.

    Article  PubMed  CAS  Google Scholar 

  13. Rubio-Beltrán E, Labastida-Ramírez A, Villalón CM, MaassenVanDenBrink A. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97. https://doi.org/10.1016/j.pharmthera.2018.01.005.

    Article  PubMed  CAS  Google Scholar 

  14. Negro A, Koverech A, Martelletti P. Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. J Pain Res. 2018;11:515–26. https://doi.org/10.2147/JPR.S132833.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Three doses of lasmiditan (50 mg, 100 mg and 200 mg) compared to placebo in the acute treatment of migraine (SPARTAN). 2017. Available from: https://www.clinicaltrials.gov/ct2/show/record/NCT02605174?term=lasmiditan&rank=1. https://investor.lilly.com/releasedetail.cfm?ReleaseID=1036101

  16. An open-label, long-term, safety study of lasmiditan for the acute treatment of migraine (GLADIATOR). 2017. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02565186?term=GLADIATOR&rank=3.

  17. Sundrum T, Walker CS. PACAP receptors in the trigeminovascular system: implications for migraine. Br J Pharmacol. 2017; https://doi.org/10.1111/bph.14053.

  18. Edvinsson L, Tatji J, Szalardy L, Vecsei L. PACAP and its role in primary headaches. J Headache Pain. 2018;19(1):21. https://doi.org/10.1186/s10194-018-0852-4.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  19. Waschek JA, Baca SM, Akerman S. PACAP and migraine headache: immunomodulation of neural circuits in autonomic ganglia and brain parenchyma. J Headache Pain. 2018;19(1):23. https://doi.org/10.1186/s10194-018-0850-6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  20. Akerman S, Goadsby PJ. Neuronal PAC1 receptors mediate delayed activation and sensitization of trigeminocervical neurons: relevance to migraine. Sci Transl Med. 2015;7(308):308ra157. https://doi.org/10.1126/scitranslmed.aaa7557.

    Article  PubMed  Google Scholar 

  21. Puledda F, Goadsby PJ. An update on non-pharmacological neuromodulation for the acute and preventive treatment of migraine. Headache. 2017;57(4):685–91. https://doi.org/10.1111/head.13069.

    Article  PubMed  Google Scholar 

  22. Lipton RB, Dodick DW, Silberstein SD, Saper JR, Aurora SK, Pearlman SH, et al. Single-pulse transcranial magnetic stimulation for acute treatment of migraine with aura: a randomized, double-blind, parallel-group, sham-controlled trial. Lancet Neurol. 2010;9(4):373–80. https://doi.org/10.1016/S1474-4422(10)70054-5.

    Article  PubMed  Google Scholar 

  23. Bhola R, Kinsella E, Giffin N, Lipscombe S, Ahmed F, Weatherall M, et al. Single-pulse transcranial magnetic stimulation (sTMS) for the acute treatment of migraine: evaluation of outcome data for the UK post market pilot program. J Headache Pain. 2015;16:535. https://doi.org/10.1186/s10194-015-0535-3.

    Article  PubMed  Google Scholar 

  24. Starling AJ, Tepper SJ, Marmura MJ, Shamim EA, Robbins MS, Hindiyeh N, et al. A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study). Cephalalgia. 2018;1: 333102418762525:1038–48. https://doi.org/10.1177/0333102418762525.

    Article  Google Scholar 

  25. Riederer F, Penning S, Schoenen J. Transcutaneous supraorbital nerve stimulation (t-SNS) with the Cefaly device for migraine prevention: a review of the available data. Pain Ther. 2015;4:135–47. https://doi.org/10.1007/s40122-015-0039-5.

    Article  PubMed Central  Google Scholar 

  26. Magis D, D’Ostilio K, Thibaut A, de Pasqua V, Gerard P, Hustinx R, et al. Cerebral metabolism before and after external trigeminal nerve stimulation in episodic migraine. Cephalalgia. 2017;37(9):881–91. https://doi.org/10.1177/0333102416656118.

    Article  PubMed  Google Scholar 

  27. Schoenen J, Vandersmissen B, Jeangette S, Herroelen L, Vandenheede M, Gerard P, et al. Migraine prevention with a supraorbital transcutaneous stimulator: a randomized controlled trial. Neurology. 2013;80:697–704. https://doi.org/10.1212/WNL.0b013e3182825055.

    Article  PubMed  Google Scholar 

  28. Magis D, Sava S, d’Elia TS, Baschi R, Schoenen J. Safety and patients’ satisfaction of transcutaneous supraorbital neurostimulation (tSNS) with the Cefaly device in headache treatment: a survey of 2,313 headache sufferers in the general population. J Headache Pain. 2013;14(95) https://doi.org/10.1186/1129-2377-14-95.

  29. Yarnitsky D, Volokh L, Ironi A, Weller B, Shor M, Shifrin A, et al. Nonpainful remote electrical stimulation alleviates episodic migraine pain. Neurology. 2017;88:1250–5. https://doi.org/10.1212/WNL.0000000000003760.

    Article  PubMed  Google Scholar 

  30. Oshinsky ML, Murphy AL, Hekierski H Jr, Cooper M, Simon BJ. Noninvasive vagus nerve stimulation as treatment for trigeminal allodynia. Pain. 2014;155(5):1037–42. https://doi.org/10.1016/j.pain.2014.02.009.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Chen SP, Ay I, de Morais AL, et al. Vagus nerve stimulation inhibits cortical spreading depression. Pain. 2016;157(4):797–805. https://doi.org/10.1097/j.pain.0000000000000437.

    Article  PubMed  PubMed Central  Google Scholar 

  32. Goadsby PJ, Grosberg BM, Mauskop A, Cady R, Simmons KA. Effect of noninvasive vagus nerve stimulation on acute migraine: an open-label pilot study. Cephalalgia. 2014;34(12):986–93. https://doi.org/10.1177/0333102414524494.

    Article  PubMed  CAS  Google Scholar 

  33. Tassorelli C, Grazzi L, De Tommaso M, et al. The PRESTO Trial. Neurology 2018; 90 (15 Supplement).

  34. Juan Y, Shu O, Jinhe L, Na Y, Yushuang D, Weiwei D, et al. Migraine prevention with percutaneous mastoid electrical stimulator: a randomized double-blind controlled trial. Cephalalgia. 2017;37(13):1248–56. https://doi.org/10.1177/0333102416678623.

    Article  PubMed  Google Scholar 

  35. Wilkinson D, Ade KK, Rogers LL, Attix DK, Kuchibhatla M, Slade MD, et al. Preventing episodic migraine with caloric vestibular stimulation: a randomized controlled trial. Headache. 2017;57:1065–87. https://doi.org/10.1111/head.13120.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Mayo Clinic Arizona, Scottsdale, AZ, USA

    Kate W. Grimsrud & Rashmi B. Halker Singh

Authors
  1. Kate W. Grimsrud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rashmi B. Halker Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kate W. Grimsrud.

Ethics declarations

Conflict of Interest

Kate W. Grimsrud declares no conflict of interest. Rashmi B. Halker Singh has received consulting fees from Amgen and Allergan.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Episodic Migraine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Grimsrud, K.W., Halker Singh, R.B. Emerging Treatments in Episodic Migraine. Curr Pain Headache Rep 22, 61 (2018). https://doi.org/10.1007/s11916-018-0716-2

Download citation

  • Published:

  • DOI: https://doi.org/10.1007/s11916-018-0716-2

Keywords

Search

Navigation